Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-1093a in Patients With Chronic Kidney Disease
NCT02299661Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of DS-1093a in anemia of chronic kidney disease (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Plasma concentrations of DS-1093a at 28 days and Change in serum erythropoietin concentrations at 6 days. Started Nov 2014; status: completed.
02
Drugs
DS-1093a
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT02299661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02299661.